Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-10-23
1999-11-16
Celsa, Bennett
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514540, 514588, 514619, 514851, 560 33, 564 59, 564160, 564161, 564192, A61K 3800, A01N 3718
Patent
active
059858249
ABSTRACT:
Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.
REFERENCES:
patent: 5637613 (1997-06-01), Renaut et al.
patent: 5674898 (1997-10-01), Cheng et al.
Cheng, S.H. et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cyctic fibrosis. Cell 63:827-834 (1990).
Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and Riordan, J.R. Multiple proteolytic systems including proteasome, contribute to CFTR processing. Cell 83:129-135 (1995).
Ward, C.L., Omura, S., & Kopito, R.R. Degradation of CFTR by the uniquitin-proteasome pathway. Cell 83:121-127 (1995).
Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., and Welsh, M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761-764 (1992).
Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., & Kopito, R.R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation, J. Biol. Chem. 271:635-638 (1996).
Cheng, S.H. et al. Functional activation of the cystic fibrosis trafficking mutant .kappa.-CFTR by overexpression. Am. J. Physiol. 268L615-L624 (1995).
Hartl, F.U. Molecular changes in cellular protein folding. Nature 381:571-580 (1996).
Pind, S., Riordan, J.R., and Williams, D.B. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J.Biol. Chem. 269:12784-12788 (1994).
Umezawa, H. et al. Structure of antitumor antibiotic, spergualin. J. Antibiotics 34:1622-1624 (1981).
Nadler, S.G., Tepper, M.A., Schacter, B., and Mazzucco. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258:484-486 (1992).
Nadeau, K., Nadler, S.G., Saulnier, M., Tepper, M.A., and Walsh, C.T. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs Hsc70 and Hsp90. Biochemistry 33:2561-2567.
Marshall, J. et al. Stoichiometry of recombinant cystic fibrosis transmembrane conductance regulator in epithelial cells and its functional reconstitution into cells in vitro. J. Biol. Chem. 269:2987-2995 (1994).
Jefferson, D.M. et al. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am. J. Physiol. 259:L496-L505 (1990).
Tepper, M.A., Nadler, S.G., Esselstyn, J.M., and Sterbenz, K.G. Deoxyspergualin inhibits .kappa. light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-.kappa.B activation. J. Immunol. 155:2427-2436 (1995).
Yankaskas, J.R. et al. Papilloma virus immortalized tracheal epithelial cells retain a well-differentiated phenotype. Am. J. Physiol. 264:C1219-C1230 (1993).
Grubman, S.A. et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic bilary epithelial cell lines. Gastroenterology 108:584-592 (1995).
Dalemans, W. et al. Altered chloride ion channel kinetics associated with .DELTA.F508 cystic fibrosis mutation. Nature 354:526-528 (1991).
Howard, M., Frizzell, R.A., and Bedwell, D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Genetics 2:467-469 (1996).
Rubenstein, R.C., Brusilow, S.W., Hamosh, A., and Zeitlin, P.L. Clinical trials of 4-phenylbutyrate for correction of sweat duct abnormalities in .DELTA.F508 homozygous cystic fibrosis patients. Pediat. Pulmonology 13:259 (1996).
Nossner, E., Goldberg, J.E., Naftzger, C., Lyu, S.C., Clayberger, C., and Krensky, A.M. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J. Exp. Med. 183:339-348 (1996).
Yang, I.C.H., Cheng, T.H., Wang, F., Price, E.M., and Hwang, T.C. Modulation of CFTR chloride channels by calyculin A and genistein. Am. J. Physiol. 272:C142-C155 (1997).
Hamill, O.P., Marty, A., Neher, E, Sakmann, B., and Sigworth, F.J. Improved patch clamp techniques for high resolution current recordings from cells and cell-free membrane patches. Pflugers Arch. 391:85-100 (1981).
Egan, M.E. et al. Defection regulation of outwardly rectifying chloride channel by protein kinase A corrected by insertion of CFTR. Nature 358:581-584 (1992).
Anderson, M.P. et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253:202-205 (1991).
Nadler, S.G. et al. Elucidating the Mechanism of Action of the Immunosuppressant 15-Deoxyspergualin. Therapeutic Drug Monitoring 17:700-703 (1995).
Halloran, P.F. Molecular mechanisms of new immunosuppressants. Clinical Transplantation 10:118-123 (1996).
Edgington, S.M. Therapeutic Applications of Heat Shock Proteins. Bio/Technology 13:1442-1444 (1995).
Sheppard D.N. and Ostedgaard, L.S. Understanding how cystic fibrosis mutations cause a loss of Cl-channel function. Mol. Med. Today 2(7):290-297 (1996).
Yang et al., PNAS USA vol. 90 pp. 9480-9484 (Oct. 1993).
Brown et al., Cell Stress & Chaperones (1996) 1(2) 117-125.
Cheng Seng Hing
Jiang Canwen
Celsa Bennett
Dugan Deborah A.
Genzyme Corporation
LandOfFree
Methods and compositions for treating cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating cystic fibrosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1324719